ChemoCentryx
CCXI
#3561
Rank
HK$29.08 B
Marketcap
HK$404.48
Share price
0.00%
Change (1 day)
33.72%
Change (1 year)

Revenue for ChemoCentryx (CCXI)

Revenue in 2022 (TTM): HK$0.29 Billion

According to ChemoCentryx's latest financial reports the company's current revenue (TTM ) is HK$0.28 Billion. In 2021 the company made a revenue of HK$0.24 Billion a decrease over the revenue in the year 2020 that were of HK$0.49 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for ChemoCentryx from 2011 to 2022

Annual revenue

Year Revenue Change
2022 (TTM) HK$0.29 B16.85%
2021 HK$0.24 B-50.17%
2020 HK$0.49 B78.28%
2019 HK$0.27 B-16.61%
2018 HK$0.33 B-47.91%
2017 HK$0.64 B626.88%
2016 HK$88.67 M
2015 N/A
2014 N/A-100%
2013 HK$46.99 M11.87%
2012 HK$42 M-82.93%
2011 HK$0.24 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Biogen
BIIB
HK$78.31 B 26,958.87%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
HK$464.02 B 160,233.33%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
HK$329.50 B 113,751.55%๐Ÿ‡ฌ๐Ÿ‡ง UK
Bristol-Myers Squibb
BMY
HK$373.69 B 129,023.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
HK$716.91 B 247,612.37%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
HK$279.85 B 96,596.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$488.46 B 168,679.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
HK$130.51 B 44,996.77%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Merck
MRK
HK$499.74 B 172,574.73%๐Ÿ‡บ๐Ÿ‡ธ USA